News: NIH researchers develop AI tool with potential to more precisely match cancer drugs to patients nih.gov/news-events/ne…

New NCI MEDIA ADVISORY features our work on PERCEPTION: an #ArtificialInteligence tool with potential to more precisely match cancer drugs to patients! tinyurl.com/nhhzz3bs #PrecisionMedicine #CancerResearch NCI Center for Cancer Research

Excited to share our work out now at NEJM AI, evaluating the capabilities and limitations of LLMs in oncology.

Thanks to all the co-authors - Dr. Dinakaran, Dr. Zhao, Eytan Ruppin, MD, PhD, Baris Turkbey MD, Deborah Citrin, Krishnan Patel, MD

ai.nejm.org/stoken/default… #LLMs #AI #Oncology #NCI

Metabolic barriers to cancer immunotherapy nature.com/articles/s4157…

📣Happy to share our new article 'Comparative Evaluation of LLMs in Clinical Oncology' ai.nejm.org/doi/full/10.10…
👍Congratulations to Dr. Rydzewski , Dr. Dinakaran, Dr. Zhao Eytan Ruppin, MD, PhD Deborah Citrin Krishnan Patel, MD
#CancerResearch #TeamScience #LLMs

Only 472 of 89,221 (0.5%) trials looked at gender differences.
Even so, there were differences
Nature Communications
nature.com/articles/s4146…

This is just a small glimpse, but we are so proud of all of the hard work and fantastic research presented by our CCR fellows and staff at #AACR24 ! NCI Cancer Training 👏

AACR 2024 poster day, featuring some of our CDSL fellows!
linkedin.com/posts/nci-cent…

Our work 'Novel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells' is published today in Cancer Discovery (aacrjournals.org/cancerdiscover…). Using genetic tools, in 2019 Cancer Dependency Map Sanger and others reported WRN as a synthetic-lethal target in MSI cell line. 1/5

During this session, J. Balthasar highlighted how most ADC tox are caused by early payload release. His team developed binding molecules to neutralize the circulating payload.

24h after the talk, Merck announced a deal to acquire the technology for 208M.

fiercebiotech.com/biotech/merck-…

NEW content online! Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications dlvr.it/T5Fz27

💫DON’T MISS Nature Cancer “Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers” #immunotherapy

Read it here 👇
nature.com/articles/s4301…

1/ We are extremely excited to share our new manuscript published Cancer Cell! Kudos to co-first authors Avishay Spitzer, MD, PhD 🎗️💔, Simon Gritsch and Masashi Nomura for seminal work, to co-PIs Mario Suva, Dan P. Cahill and Keith Ligon and to all contributors.

What is the role of the TME in lung cancer evolution? We are excited to share our new TRACERx paper “Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer” at #AACR24 , out in Cancer Discovery today rb.gy/q484j9 Tweetorial👇

Most cancer drugs granted accelerated approval did not demonstrate benefit in overall survival or quality of life within 5 years of accelerated approval. ja.ma/3J3zZMi #AACR24

Sex differences in tissue immunity | Science science.org/doi/10.1126/sc…

Agnostic ADCs are finally here. Huge opportunity for thousands of patients, but plenty of challenges! We need better biomarkers, an improved understanding of ADC sequencing and strategies to decrease toxicities. acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… Roberto Pestana, MD G Curigliano MD PhD Chiara Corti Sara Tolaney

In the latest issue! Cancer biomarkers: Emerging trends and clinical implications for personalized treatment dlvr.it/T4yFdY

Very exciting abstract presentation at AACR in San Diego: An innovative Trop2/Nectin4 targeted bispecific antibody drug conjugate (ADC) in bladder urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and beyond

🔍This innovative bispecific Trop2/Nectin4 targeting ADC…